| 1 | Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer显示文摘BACKGROUND In order to improve risk stratification and clinical management of the pancreatic ductal adenocarcinoma(PDAC),the American Joint Committee on Cancer(AJCC)has published its eighth edition staging manual.Some major changes have been introduced in the new staging system for both T and N categories.Given the rarity of resectable disease,distal pancreatic cancer is likely underrepresented in the published clinical studies,and how the impact of the staging system actually reflects on to clinical outcomes remain unclear.AIM To validate the AJCC 8th edition of TNM staging in distal PDAC.METHODS A retrospective cohort study was performed in seven academic medical centers in the United States.Clinicopathological prognostic factors associated with progression-free survival(PFS)and overall survival(OS)were evaluated through univariate and multivariate analyses.RESULTS Overall,454 patients were enrolled in the study,and were divided into 2 subgroups:Invasive intraductal papillary mucinous neoplasms(IPMN)(115 cases)and non-IPMN associated adenocarcinoma(339 cases).Compared to invasive IPMN,non-IPMN associated adenocarcinomas are more common in relatively younger patients,have larger tumor size,are more likely to have positive lymph nodes,and are associated with a higher tumor(T)stage and nodal(N)stage,lymphovascular invasion,perineural invasion,tumor recurrence,and a worse PFS and OS.The cohort was predominantly categorized as stage 3 per AJCC 7th edition staging manual,and it’s more evenly distributed based on 8th edition staging manual.T and N staging of both 7th and 8th edition sufficiently stratify PFS and OS in the entire cohort,although dividing into N1 and N2 according to the 8th edition does not show additional stratification.For PDAC arising in IPMN,T staging of the 7th edition and N1/N2 staging of the 8th edition appear to further stratify PFS and OS.For PDAC without an IPMN component,T staging from both versions fails to stratify PFS and OS.CONCLUSION The AJCC 8th edition TNM staging system provides even distribution for the T staging,however,it does not provide better risk stratification than previous staging system for distal pancreatic cancer. | Feng Yin Mohammed Saad Hao Xie Jingmei Lin Christopher R Jackson Bing Ren Cynthia Lawson Dipti M Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W Schultz Dongwei Zhang Courtney L Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Xiuli Liu | 2020 | World Journal of Gastrointestinal Pharmacology and Therapeutics2020，11，2： | 1 |
| 2 | 脾血管浸润是胰体尾癌切除术后的不良预后因素显示文摘背景:由于较高的远处转移率,胰体尾癌是致死率最高的肿瘤之一。本研究旨在评估脾血管浸润对于胰体尾癌切除术患者的预后价值。方法:在这项回顾性研究中,我们收集了454例胰体尾癌患者的临床病理资料,通过单因素和多因素分析明确本组患者无进展生存(PFS)和总体生存(OS)的预后影响因素,重点关注脾动/静脉浸润的预后价值。结果:单因素分析结果显示,肿瘤较大、非导管内乳头状黏液瘤(non-IPMN)相关的腺癌、低分化、pT3期、淋巴结转移、脉管浸润、神经浸润、病理学脾静脉浸润、影像学脾静脉浸润者PFS和OS均显著缩短(均P<0.05)。多因素分析证实,non-IPMN相关腺瘤、pT3期、pN1-2期及术后辅助化疗是PFS和OS的独立危险因素;此外,肿瘤较大和影像学脾静脉浸润同时也是PFS的独立预后因素。结论:应当就如何检测和报告胰体尾癌手术标本的脾血管状态,形成一个统一的规范。 | Feng Yin Mohammed Saad Jingmei Lin Christopher R.Jackson Bing Ren Cynthia Lawson Dipti M.Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W.Schultz Dongwei Zhang Courtney L.Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Hao Xie Xiuli Liu | 2021 | Gastroenterology Report2021，9，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员